APXT’s valuation is a paradox. Despite a staggering DCF value that dwarfs its snapshot price, the market seems oblivious to this potential upside. The Altman Z-score of 4.02 suggests robust financial health, yet the high Price/Earnings ratio of 45.57 raises eyebrows about its growth expectations. With an earnings yield of just 2.19%, the stock appears overvalued relative to its earnings power. The absence of a forward P/E further clouds its growth trajectory, leaving investors to question if the market is pricing in perfection or overlooking a hidden gem.